114 Results for "

CTLA4

" in MedChemExpress (MCE) Product Catalog:
Products (114)

114 Results for "CTLA4" in MCE Product Catalog:

Cat. No.: HY-RS03301
Research Areas:  

Others

Ctla4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ctla4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-RS03299
Research Areas:  

Others

CTLA4 Human Pre-designed siRNA Set A contains three designed siRNAs for CTLA4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P99709
CAS No.: 2118349-31-6
Synonyms: LY3300054

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Lodapolimab (LY3300054) is a fully human IgG1λ anti-PD-L1 monoclonal antibody, with an EC50 of 0.075 nM against hPD-L1 and an EC50 of 0.085 nM against cynomolgus monkey PD-L1. Lodapolimab induces naive T cell activation, enhances the T cell activation effect of anti-CTLA4 antibodies, promotes anti-tumor alloreactivity, regulates innate immune pathways, and induces characteristics of adaptive immune activation. Lodapolimab can be used in research related to high-grade serous ovarian cancer and other solid tumors .
loading...
    loading...
Cat. No.: HY-P990703
CAS No.: 2649372-91-6
Synonyms: HBM-4003

Target:  

CTLA-4

Research Areas:  

Inflammation/Immunology

Porustobart (HBM-4003) is a fully human anti-CTLA-4 heavy chain only antibody (HCAb). Porustobart can significantly improve the depletion of regulatory T cells (Treg cells) with high CTLA-4 expression in tumor tissues by enhancing ADCC activity. Porustobart can be used for tumor research .
loading...
    loading...
Cat. No.: HY-P99844
CAS No.: 2307144-64-3
Synonyms: ALPN-202; CD80 vIgD-Fc

Target:  

CTLA-4

Research Areas:  

Cancer

Davoceticept (ALPN-202; CD80 vIgD-Fc) is a variant CD80 vIgD-Fc fusion protein targeting CTLA-4 and PD-L1. Davoceticept consists of the (1-107) fragment of CD80 linked to IGHG1 Fc via a peptidyl linker. The expression system of Davoceticept is usually CHO (Chinese Hamster Ovary) cells .
loading...
    loading...
Cat. No.: HY-179228
CAS No.: 1246964-08-8
Target:  

CTLA-4 TGF-beta/Smad

Research Areas:  

Cancer

AN02 is a derivative of Curcumin (HY-N0005). AN02 inhibits the proliferation and clonogenicity, migration and invasion of ovarian cancer cells. AN02 dose-dependently upregulates the expression of APC and mediates the degradation of CTLA-4 through SMAD4. In the small xenograft model, AN02 significantly inhibits tumor growth and reverses the tumor immune-suppressive microenvironment. AN02, when combined with Ipilimumab (HY-P9901), can enhance efficacy and inhibit epithelial-mesenchymal transition. AN02 can be used for the study of ovarian cancer .
loading...
    loading...
Cat. No.: HY-P99354
CAS No.: 2329669-78-3
Synonyms: Anti-Human CTLA4xLAG3; XmAb-22841; Pavunalimab

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Bavunalimab (Anti-Human CTLA4xLAG3) is a bispecific human anti-CTLA-4/LAG-3 monoclonal antibody. Bavunalimab activates T cells in NSG mice. Bavunalimab can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P991566
CAS No.: 2983061-18-1

Target:  

CTLA-4

Research Areas:  

Cancer

KD6001 is a humanized IgG1κ monoclonal antibody, targeting CTLA4. KD6001 significantly disrupts CTLA-4 interactions with CD80 (IC50: 16 ng/mL) and CD86. KD6001 enhances IL-2 and IFNγ expression in PHA-activated human lymphocytes and exhibits potent antitumor effects. KD6001 effectively inhibits tumor growth in MC38, B16, and Hepa1-6 tumor mice model. KD6001 can be used for cancers research, such as advanced melanoma, hepatocellular carcinoma and liver cancer .
loading...
    loading...
Cat. No.: HY-P991775

Target:  

CTLA-4

Research Areas:  

Inflammation/Immunology

Anti-Rat CTLA-4 Antibody (WKH203) reacts with rat CTLA-4. Anti-Rat CTLA-4 Antibody (WKH203) binds to the CTLA-4 protein disrupts the key signaling mechanisms linked to the suppression of T cell activity, triggering T cells readily and enhancing the immune system’s capacity to identify and eliminate cancer. Recommend Isotype Controls: Mouse IgG1 kappa, Isotype Control (HY-P99977) .
loading...
    loading...
Cat. No.: HY-P991827

Target:  

CTLA-4

Research Areas:  

Cancer

Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) reacts with mouse cytotoxic T lymphocyte antigen-4 (CTLA-4, CD152). Anti-Mouse CTLA-4 Antibody (UC10-4F10-11) promotes T cell co-stimulation by blocking CTLA-4 binding to the B7 co-receptors, allowing for CD28 binding. Recommend Isotype Controls: Polyclonal Armenian hamster IgG, Isotype Control (HY-P990305) .
loading...
    loading...
Cat. No.: HY-P990848

Target:  

CTLA-4

Research Areas:  

Infection Inflammation/Immunology

Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV) .
loading...
    loading...
Cat. No.: HY-P990041
CAS No.: 2750031-14-0
Synonyms: ADG-116

Target:  

CTLA-4

Research Areas:  

Inflammation/Immunology Cancer

Firastotug is an IgG1κ antibody targeting CTLA4. CTLA4 is a cytotoxic T lymphocyte-associated protein and a key immune checkpoint in the fields of autoimmunity and cancer .
loading...
    loading...
Cat. No.: HY-P990722
CAS No.: 2599198-80-6

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

Danvilostomig is an anti-CTLA4/PDCD1 monoclonal antibody .
loading...
    loading...
Cat. No.: HY-P990945
CAS No.: 2850355-80-3

Target:  

CTLA-4

Research Areas:  

Inflammation/Immunology

HY-P990945 is an CTLA4-targeting IgG1κ type humanized antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P990739
CAS No.: 2460399-39-5
Synonyms: BA-3071
Target:  

CTLA-4

Research Areas:  

Inflammation/Immunology

Evalstotug is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
loading...
    loading...
Cat. No.: HY-P990775
CAS No.: 2760549-50-4
Synonyms: XTX101

Target:  

CTLA-4

Research Areas:  

Inflammation/Immunology

Vilastobart is an anti-CTLA4 human IgG1 κ monoclonal antibody . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
loading...
    loading...
Cat. No.: HY-P991139
CAS No.: 3014361-57-7
Synonyms: YH-001; C-17226

Target:  

CTLA-4

Research Areas:  

Cancer

Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .
loading...
    loading...
Cat. No.: HY-P990385

Target:  

Inhibitory Antibodies

Research Areas:  

Inflammation/Immunology

Anti-CTLA-4/CD152 Antibody is an anobody that targets CTLA-4/CD152. The Anti-CTLA-4/CD152 Antibody has a huIgG4SP type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-CTLA-4/CD152 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).
loading...
    loading...
Cat. No.: HY-L184
1,203 compounds

Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer.

MCE designs a unique collection of 1,203 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Cat. No.: HY-P991960

Research Areas:  

Cancer

JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a Kd of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.
loading...
    loading...